3A\C); no immunoreactivity for FGF1 was observed for HSCs in liver sections co\stained with desmin (Fig
3A\C); no immunoreactivity for FGF1 was observed for HSCs in liver sections co\stained with desmin (Fig. presence of hepatic fibrosis, biliary proliferation, inflammation, senescence, and angiogenesis. Targeting the FGF1 and miR\16 axis may provide therapeutic options in treating cholangiopathies such as PSC. Abstract Cholangiocytes are the target cells FRAP2 in various rodent models of biliary…